Austrália - inglês - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: propylene glycol; dl-alpha-tocopherol; ethanol; gelatin; corn glycerides; peg-40 hydrogenated castor oil; titanium dioxide; glycerol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - changes as described in the letter 23 december 1998 from b wall.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: gelatin; peg-40 hydrogenated castor oil; corn glycerides; dl-alpha-tocopherol; titanium dioxide; iron oxide black; ethanol; glycerol; propylene glycol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - changes as described in the letter 23 december 1998 from b wall

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; silicon dioxide; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin - ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. ceptolate (mycophenolate mofetil) is indicated for the prophylaxis of organ rejection in paediatric patients with a body surface area of greater than or equal to 1.25 square metres, receiving allogeneic renal transplants.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: povidone; titanium dioxide; iron oxide yellow; iron oxide red; croscarmellose sodium; gelatin; pregelatinised maize starch; indigo carmine; magnesium stearate - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, modified release - excipient ingredients: lactose monohydrate; titanium dioxide; hypromellose; sodium lauryl sulfate; iron oxide red; magnesium stearate; iron oxide yellow; ethylcellulose; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - advagraf xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, modified release - excipient ingredients: hypromellose; iron oxide yellow; gelatin; sodium lauryl sulfate; titanium dioxide; ethylcellulose; iron oxide red; magnesium stearate; lactose monohydrate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - advagraf xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, modified release - excipient ingredients: iron oxide yellow; hypromellose; iron oxide red; titanium dioxide; lactose monohydrate; ethylcellulose; magnesium stearate; sodium lauryl sulfate; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - advagraf xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 1.02 mg (equivalent: tacrolimus, qty 1 mg) - capsule - excipient ingredients: hypromellose; dichloromethane; lactose; ethanol absolute; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 0.51 mg (equivalent: tacrolimus, qty 0.5 mg) - capsule - excipient ingredients: dichloromethane; lactose; ethanol absolute; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 0.51 mg (equivalent: tacrolimus, qty 0.5 mg) - capsule - excipient ingredients: dichloromethane; ethanol absolute; hypromellose; magnesium stearate; croscarmellose sodium; lactose; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.